Probiotics and prevention of Clostridium difficile infection

被引：30

作者：

Goldstein, E. J. C. ^{[1
,2
]}

Johnson, S. J. ^{[3
]}

Maziade, P. -J. ^{[4
]}

Evans, C. T. ^{[5
,6
,7
]}

Sniffen, J. C. ^{[8
]}

Millette, M. ^{[9
]}

McFarland, L. V. ^{[10
]}

机构：

[1] RM Alden Res Lab, Santa Monica, CA USA

[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[3] Loyola Sch Med, Chicago, IL USA

[4] Pierre Le Gardeur Hosp, Terrebonne, PQ, Canada

[5] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA

[6] Northwestern Univ, Ctr Healthcare Studies, Chicago, IL 60611 USA

[7] Edward Hines Jr VA Hosp, Chicago, IL USA

[8] Florida Hosp, Orlando, FL USA

[9] BioK Plus Int Inc, Laval, PQ, Canada

[10] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA

来源：

ANAEROBE | 2017年 / 45卷

关键词：

Probiotic; Bio-K; Saccharomyces boulardii; C; difficile; Lactobacillus rhamnosus GG; Lactobacillus acidophilus CL1285; Lactobacillus casei LBC80R; Lactobacillus rhamnosus CLR2; LACTOBACILLUS-ACIDOPHILUS CL1285; ANTIBIOTIC-ASSOCIATED DIARRHEA; CASEI LBC80R; COST-EFFECTIVENESS; DOUBLE-BLIND; COMBINATION; EPIDEMIOLOGY; INPATIENTS; SURVIVAL; RELAPSE;

D O I：

10.1016/j.anaerobe.2016.12.007

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The role of probiotics as adjunctive measures in the prevention of Clostridium difficile infection (CDI) has been controversial. However, a growing body of evidence has suggested that they have a role in primary prevention of CDI. Elements of this controversy are reviewed and the proposed mechanisms of action, the value and cost effectiveness of probiotics are addressed with a focus on three agents, Saccharomyces boulardii, Lactobacillus rhamnosus GG and the combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC8OR, Lactobacillus rhamnosus CLR2 (Bio-K+). (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：114 / 119

页数：6

共 50 条

[21] Probiotics to Prevent Clostridium difficile Infection in Patients Receiving Antibiotics
Goldenberg, Joshua Z.
Mertz, Dominik
Johnston, Bradley C.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (05): : 499 - 500
[22] The management of Clostridium difficile infection:: Antibiotics, probiotics and other strategies
Senok, A. C.
Rotimi, V. O.
JOURNAL OF CHEMOTHERAPY, 2008, 20 (01) : 5 - 13
[23] Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic
Hell, M.
Bernhofer, C.
Stalzer, P.
Kern, J. M.
Claassen, E.
BENEFICIAL MICROBES, 2013, 4 (01) : 39 - 51
[24] A New Strategy for the Prevention of Clostridium difficile Infection
Howerton, Amber
Patra, Manomita
Abel-Santos, Ernesto
JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (10): : 1498 - 1504
[25] Pathway to Prevention of Nosocomial Clostridium difficile Infection
Goldstein, Ellie J. C.
Johnson, Stuart
Maziade, Pierre-Jean
McFarland, Lynne V.
Trick, William
Dresser, Linda
Millette, Mathieu
Mazloum, Hadi
Low, Donald E.
CLINICAL INFECTIOUS DISEASES, 2015, 60 : S148 - S158
[26] Prevention and medical management of Clostridium difficile infection
Shannon-Lowe, J.
Matheson, N. J.
Cooke, F. J.
Aliyu, S. H.
BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 : 641 - 646
[27] Clostridium difficile Infection Prevention Bundle Implementation
Ling, Moi Lin
Jin, Pinhong
Tan, Kwee Yuen
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2020, 41 : S170 - S171
[28] Prevention of Infection due to Clostridium (Clostridioides) difficile
Krishna, Amar
Chopra, Teena
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2021, 35 (04) : 995 - 1011
[29] Breakthroughs in the treatment and prevention of Clostridium difficile infection
Larry K. Kociolek
Dale N. Gerding
Nature Reviews Gastroenterology & Hepatology, 2016, 13 : 150 - 160
[30] Breakthroughs in the treatment and prevention of Clostridium difficile infection
Kociolek, Larry K.
Gerding, Dale N.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (03) : 150 - 160

← 1 2 3 4 5 →